Twenty eight patients treated with selective serotonin reuptake inhibitors/venlafaxine were
randomized to a three-day (short) or 14-day (longer) anti—depressant taper and openly …

In 2008, Chouinard and Chouinard [1] published an editorial in Psychotherapy and
Psychosomatics applying the basic pharmacological concepts of withdrawal to symptoms …

The course and duration of therapy, withdrawal syndromes, and resistance to therapy are
important clinical topics in antidepressant therapy. The reviewed clinical evidence may help …

Sudden or tapered withdrawal from treatment with antidepressants, including monoamine
oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and serotonin selective …

A substantial proportion of the burden of depression arises from its recurrent nature. The risk
of relapse after antidepressant medication (ADM) discontinuation is high but not uniform …

Withdrawal from tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs)
and selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) can …

Recent media reports have refocused attention on the syndromic manifestation experienced
by some patients as they discontinue their antidepressant medication (“discontinuation …

Approximately half of the tens of millions of people currently taking antidepressants will
experience withdrawal symptoms when they try to reduce or come off them. Nearly half of …

Objective Antidepressants are at best 50–55% effective. Non‐compliance and the
antidepressant discontinuation syndrome (ADS) are causally related yet poorly appreciated …

The present overview investigates whether different antidepressants have differing
discontinuation symptoms upon treatment cessation, if these symptoms vary between …